An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Opdivo Qvantig (nivolumab and hyaluronidase ... The switch from the original IV formulations improves the ease of administration for the drugs, reducing the time patients have to spend in clinics ...

Participants were randomized to receive intravenous (IV) Opdivo or placebo at 240 mg every two weeks. They received adjuvant treatment for up to 1 year. Stratification factors included tumor PD-L1 ...

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma. Among patients with ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

compared to Opdivo monotherapy after complete resection of stage III-IV melanoma. The primary endpoint of the trial is recurrence-free survival (RFS). Secondary endpoints include overall survival ...

In adjuvant melanoma, Opdivo(R) (nivolumab) remains a standard of care for adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV ...